オプションチェーンは、IperionXの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、IperionXの市場センチメントを評価します。.

IperionX (NASDAQ:IPX) 株価情報, オプションチェーン

IperionX Ltd produces titanium critical minerals, titanium powders, and titanium end products for various industries. The company's breakthrough titanium technologies have demonstrated the potential to produce titanium products that are sustainable, recyclable, and have low carbon intensity. IperionX is producing titanium metal powders from titanium scrap at its operational pilot facility in Utah, It also owns a titan critical minerals project, the Titan Project, covering over 11,000 acres of critical minerals that include titanium, rare earth elements, silica sand, and zircon in Tennessee, United States.

IperionX Limited - American Depositary Share

IperionX Ltd

Tachyon Protocol

Impax Asset Management Group PLC

Inpex Corp

Inflection Point Acquisition Corp. II - Class A Ordinary Shares

Inflection Point Acquisition Corp II

Inflection Point Acquisition Corp. II - Unit

Inflection Point Acquisition Corp. II - Warrant

RBC Capital analyst Walter Spracklin maintains TFI International (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TFII#TSX">TFII</a>) with a Outperform and lowers the price target from C$156 to C$127.

News

Price Target

Analyst Ratings

TSX:TFII

RBC Capital Maintains Outperform on TFI International, Lowers Price Target to C$127

UBS analyst A.J. Rice maintains Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) with a Neutral and raises the price target from $16.5 to $18.5.

UBS Maintains Neutral on Pediatrix Medical Group, Raises Price Target to $18.5

UBS analyst Lloyd Walmsley maintains Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) with a Buy and raises the price target from $5560 to $5960.

BKNG

UBS Maintains Buy on Booking Holdings, Raises Price Target to $5960

RBC Capital analyst Walter Spracklin maintains TFI International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFII#NYSE">TFII</a>) with a Outperform and lowers the price target from $156 to $127.

TFII

RBC Capital Maintains Outperform on TFI International, Lowers Price Target to $127

RBC Capital analyst Scott Heleniak maintains Ryan Specialty Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYAN#NYSE">RYAN</a>) with a Sector Perform and lowers the price target from $73 to $72.

RYAN

RBC Capital Maintains Sector Perform on Ryan Specialty Hldgs, Lowers Price Target to $72

WIIM

EXPI

eXp World Holdings shares are trading lower. The company reported Q4 financial results.

CrowdStrike Holdings, Inc. (NADSAQ:CRWD) shares are trading lower on Friday following a report suggesting that the Department of Justice and the Securities and Exchange Commission are investigating the company&#8217;s <a href="https://www.benzinga.com//node/43878029">$32 million deal </a>with Carahsoft Technology Corp.
What To Know: The deal between CrowdStrike and Carahsoft, a technology distributor, aimed to provide cybersecurity tools to the Internal Revenue Service (IRS), according to <a href="https://www.bloomberg.com/news/articles/2025-02-21/justice-dept-sec-investigating-32-million-crowdstrike-deal-with-carahsoft?embedded-checkout=true">Bloomberg</a>. Back in 2023, Carahsoft paid CrowdStrike for the deal but the IRS never purchased the products.
CrowdStrike finalized the deal on the last day of its 2023 third-quarter. In a follow-up earnings call, CEO George Kurtz emphasized that the quarter included a significant federal government deal for identity threat protection, valued in the eight figures.
The deal is reportedly large enough that it could have impacted whether CrowdStrike met or missed Wall Street's projections for the quarter. After reporting its earnings, the company's stock rose by 10%.
CrowdStrike has not explained how it accounted for the deal, but the company stands by its accounting. In its November 2024 earnings report, it excluded $26 million from its recurring revenue, although it remains unclear if this is connected to the IRS and Carahsoft deal.
CFO Burt Podbere explained that the company deemed the transaction non-repeatable after the distributor exercised its transferability rights. Investigators have continued interviewing former CrowdStrike and IRS employees since last fall and are working to collect relevant documents.
At the time of the deal, some CrowdStrike employees raised concerns about "pre-booking" the transaction, unsure if the IRS would purchase the products. A CrowdStrike spokesperson denied these claims.
See Also: <a href="https://www.benzinga.com/insights/news/25/02/43885495/price-over-earnings-overview-regeneron-pharmaceuticals">Price Over Earnings Overview: Regeneron Pharmaceuticals</a>
CRWD Price Action: At the time of writing, CrowdStrike shares are trading 4.77% lower at $415.32, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: via Shutterstock

Movers

CRWD

What's Going On With CrowdStrike Shares Friday?

GRAL

GRAIL shares are trading lower. The company reported Q4 financial results.

Clear Secure shares are trading higher after the company board authorized a $200 million increase to its share repurchase program.

RBC Capital analyst Conor McNamara maintains Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Outperform and raises the price target from $203 to $205.

RGEN

RBC Capital Maintains Outperform on Repligen, Raises Price Target to $205

AAPL

Apple Intelligence Comes To Apple Vision Pro In April

<a href="https://www.apple.com/newsroom/2025/02/apple-intelligence-expands-to-more-languages-and-regions-in-april/#:~:text=Apple%20Intelligence%2C%20the%20personal%20intelligence,English%20for%20Singapore%20and%20India.">https://www.apple.com/newsroom/2025/02/apple-intelligence-expands-to-more-languages-and-regions-in-april/#:~:text=Apple%20Intelligence%2C%20the%20personal%20intelligence,English%20for%20Singapore%20and%20India.</a>
&nbsp;
Apple Intelligence, the personal intelligence system that delivers helpful and relevant intelligence, will soon be available in more languages, including French, German, Italian, Portuguese (Brazil), Spanish, Japanese, Korean, and Chinese (simplified) — as well as localized English for Singapore and India.
These new languages will be accessible in nearly all regions around the world with the release of iOS 18.4, iPadOS 18.4, and macOS Sequoia 15.4 in April, and developers can start to test these releases today.
With the upcoming software updates, iPhone and iPad users in the EU will have access to Apple Intelligence features for the first time, and Apple Intelligence will expand to a new platform in U.S. English with <a href="https://www.apple.com/newsroom/2025/02/apple-intelligence-comes-to-apple-vision-pro-in-april/">Apple Vision Pro</a>&nbsp;—&nbsp;helping users communicate, collaborate, and express themselves in entirely new ways.
Apple Intelligence marks an extraordinary step forward for privacy in AI and is designed to protect users' privacy at every step. It starts with on-device processing, meaning that many of the models that power Apple Intelligence run entirely on the device. For requests that require access to larger models, Private Cloud Compute extends the privacy and security of iPhone into the cloud to unlock even more intelligence.
Apple Intelligence will continue to expand with new features in the coming months, including more capabilities for Siri.

Global

'Apple Intelligence On iPhone, iPad, And Mac Expands To More Languages And Regions In April'

UBS analyst Kunal Madhukar maintains Global E Online (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBE#NASDAQ">GLBE</a>) with a Buy and lowers the price target from $68 to $64.

GLBE

UBS Maintains Buy on Global E Online, Lowers Price Target to $64

RBC Capital analyst Brian Abrahams maintains Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Sector Perform and lowers the price target from $24 to $20.

PRTA

RBC Capital Maintains Sector Perform on Prothena Corp, Lowers Price Target to $20

CENX

Century Aluminum shares are trading lower. The company reported Q4 financial results.

The U.S. Food and Drug Administration (FDA) approved Mirum Pharmaceuticals, Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRM#NASDAQ">MIRM</a>) drug to treat CTX, a very rare lipid storage disease.
CTX is a genetic metabolic disorder caused by a mutation in a gene called CYP27A1, resulting in a deficiency of the enzyme that is important to the body's ability to break down fats.
Ctexli (chenodiol) is the first FDA-<a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-cerebrotendinous-xanthomatosis-rare-lipid-storage-disease#:~:text=Today%2C%20the%20U.S.%20Food%20and,very%20rare%20lipid%20storage%20disease." target="_blank" rel="noreferrer noopener">approved</a> drug to treat cerebrotendinous xanthomatosis (CTX) in adults.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/25/02/43887175/disney-appoints-former-paramount-exec-daria-cercek-to-lead-live-action-films-reshaping-studio-leadership" rel="noreferrer noopener">Disney Appoints Former Paramount Exec Daria Cercek to Lead Live-Action Films, Reshaping Studio Leadership</a>
Due to reduced bile acid production in the liver, patients with CTX are unable to break down cholesterol in a normal way, resulting in deposition of atypical cholesterol metabolites in various places in the body including the brain, liver, skin and tendons, leading to damage to those organs and tissues.
Ctexli works to replace deficient levels of one of the bile acids, reducing the abnormal deposits of cholesterol metabolites thought to be responsible for clinical abnormalities in CTX.
The efficacy of Ctexli was evaluated in a double-blind, placebo-controlled, randomized crossover withdrawal trial.
The 24-week trial demonstrated that treatment with Ctexli, 250 milligrams three times per day, significantly reduced plasma cholestanol and urine 23S-pentol (cholesterol metabolites markedly increased in CTX patients) compared to placebo treatment.
The prescribing information for Ctexli includes a warning for liver toxicity in all patients with increased risk for liver damage in patients with pre-existing liver disease or bile duct abnormalities.
Patients should obtain liver blood tests before starting treatment, annually while on treatment, and as clinically indicated.
In January, Mirum Pharmaceuticals reported preliminary net product sales of approximately $99 million in the fourth quarter, including approximately $64 million in Livmarli net sales and approximately $35 million <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42943888/mirum-pharmaceuticals-announces-preliminary-unaudited-2024-net-product-sales-and-cash-balance-and-" rel="noreferrer noopener">from Cholbam and Chenodal</a>.
The company expects 2025 global net product sales of approximately $420 million to $435 million and positive cash flow from operations.
Price Action: Mirium stock is up 0.10% at $53.22 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/02/43883818/glaukos-delivers-mixed-q4-results-analyst-sees-growing-investor-interest-during-transition" target="_blank" rel="noreferrer noopener">Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition</a></li>
</ul>
Image: Shutterstock

Biotech

Health Care

General

MIRM

FDA Approves Mirum Pharmaceuticals' Drug As First For Genetic Disorder With Inability To Break-Down Cholesterol

Westlake Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) will release its fourth-quarter financial results, before the opening <a href="https://www.benzinga.com/quote/WLK/earnings">bell, on Monday, Feb. 24, 2025.</a>
Analysts expect the Houston, Texas-based company to report quarterly earnings at $1.17 per share, up from 53 cents per share in the year-ago period. Westlake projects quarterly revenue of $2.97 billion, compared to $2.83 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Nov. 5, the company posted weaker-than-expected third-quarter earnings.
Westlake shares fell 1.9% to close at $111.40 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/WLK/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Citigroup analyst Patrick Cunningham upgraded the stock from Neutral to Buy and cut the price target from $152 to $140 on Dec. 18, 2024. This analyst has an accuracy rate of 63%.</li>
<li>BMO Capital analyst John McNulty maintained a Market Perform rating and lowered the price target from $171 to $165 on Nov. 13, 2024. This analyst has an accuracy rate of 63%.</li>
<li>UBS analyst Joshua Raskin maintained a Neutral rating and cut the price target from $160 to $144 on Nov. 6, 2024. This analyst has an accuracy rate of 80%.</li>
<li>Wells Fargo analyst Michael Sison maintained an Overweight rating and cut the price target from $180 to $160 on Nov. 6, 2024. This analyst has an accuracy rate of 67%.</li>
<li>JP Morgan analyst Jeffrey Zekauskas maintained an Underweight rating and raised the price target from $123 to $135 on Aug. 15, 2024. This analyst has an accuracy rate of 67%.</li>
</ul>
Considering buying WLK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="597" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21040916/image-177-1024x597.png" alt="" class="wp-image-792653" style="width:640px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21040916/image-177-1024x597.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21040916/image-177-300x175.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21040916/image-177-768x448.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21040916/image-177.png 1093w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43864993/top-3-health-care-stocks-you-may-want-to-dump-in-february">Top 3 Health Care Stocks You May Want To Dump In February</a></li>
</ul>

Earnings

Markets

Trading Ideas

Top Wall Street Forecasters Revamp Westlake Price Expectations Ahead Of Q4 Earnings

UBS analyst Taylor McGinnis maintains RingCentral (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNG#NYSE">RNG</a>) with a Neutral and lowers the price target from $40 to $38.

UBS Maintains Neutral on RingCentral, Lowers Price Target to $38

RBC Capital analyst Rishi Jaluria maintains NICE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>) with a Outperform and lowers the price target from $260 to $200.

NICE

RBC Capital Maintains Outperform on NICE, Lowers Price Target to $200

VKTX

Viking Therapeutics shares are trading higher amid unconfirmed M&A rumors.

Press Releases

IperionX Partners With United Stars for U.S. Sourced Titanium Manufacturing

IperionX Titanium HAMR Furnace Installation Complete

IperionX and Vegas Fastener to Co-Produce Titanium Fasteners for U.S. Army

IperionX and Aperam Partnership to Advance a Circular Titanium Supply Chain

IperionX Achieves Major Milestone With First Successful Titanium Furnace Production Run

IperionX Completes Acquisition of Breakthrough Titanium Technologies

IperionX December 2024 Quarterly Report

IperionX Letter to Shareholders

IperionX Awarded $47.1M by the U.S. DoD to Secure U.S. Titanium Supply Chains

Alpha Metallurgical Resources, Inc. Common Stock

Alpha Metallurgical

Compania De Minas

Century Aluminum

Compass Minerals Intl

DRDGOLD Limited American Depositary Shares

DRDGold

Ferroglobe

Warrior Met Coal

Ivanhoe Electric

IperionX

Kaiser Aluminum Corporation - Common Stock

Kaiser Aluminum

Ramaco Resources, Inc. - Class A Common Stock

Ramaco Resources

Ramaco Resources, Inc. - Class B Common Stock

Mesabi Tr

MAC Copper

Materion

Metallus

McEwen Mining

Nexa Res

Radius Recycling, Inc. - Class A Common Stock

Radius Recycling

Ryerson Holding

Sibanye Stillwater

Companhia Siderurgica Nacional S.A. Common Stock

Companhia Siderurgica

SunCoke Energy

TMC the metals company Inc. - Common Stock

Comments

IperionX

IperionX (IPX) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル